MedTrace Logo

An Observational Study of the Mean Duration of Trastuzumab (Herceptin) Treatment in Participants With Early or Metastatic Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer

NCT01187381 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 250

Last updated 2017-10-20

Study results available
· View outcomes & findings →

Summary

This single arm observational study will assess the duration and safety of treatment with trastuzumab in routine clinical practice in participants with early or metastatic HER2-positive breast cancer. Data will be collected from female participants treated with trastuzumab according to the Summary of Product Characteristics and local protocols. Duration of observation for each participant is from therapy initiation until permanent discontinuation for any cause.

Conditions

Interventions

DRUG

Trastuzumab

Trastuzumab according to local standard of care and in line with the current summary of product characteristics/ local guidelines

Sponsors & Collaborators

Principal Investigators

  • Clinical Trials · Hoffmann-La Roche

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-04-14
Primary Completion
2015-10-15
Completion
2015-10-15
FDA Drug
Yes

Countries

  • Romania

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01187381 on ClinicalTrials.gov